Bendamustine: role and evidence in lymphoma therapy, an overview

References

• Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001;12:725–729.
   PubMed Web of Science ®Google Scholar
• Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002;128:603–609.
   PubMed Web of Science ®Google Scholar
• Ruffert K, Jahn H, Syrbe G, et al. Cytostasan (bendamustine) as an alternative therapeutic approach to treat malignant non-Hodgkin's lymphoma. Z Klin Med 1989;44:671–674.
   Google Scholar
• Blumenstengel K, Fricke HJ, Kath R, et al. Bendamustine (B), vincristine (O), prednisone (P) in relapsed and refractory low grade non-Hodgkin's lymphoma. Ann Hematol 1998;77(Suppl. 11):S149.
   PubMed Web of Science ®Google Scholar
• Heck HK, Preiss JM, Schmidt P. Bendamustine (B) and mitoxantrone (M) in the treatment of low grade non-Hodgkin's lymphoma (NHL). J Cancer Res Clin Oncol 1998;124(Suppl.):R147.
   Google Scholar
• Kahl C, Herold M, Hoffkes H, et al. Beandamustine, methotrexate, mitoxantrone and prednisone (BMMP) for the treatment of high grade non-Hodgkin's lymphoma. Onkologie 1997;20:406–408.
   Web of Science ®Google Scholar
• Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007;48:1299–306.
   PubMed Web of Science ®Google Scholar
• Ruffert K. Therapy of low grade non-Hodgkin's lymphoma (NHL) with bendamustine and oral etoposide. Ann Oncol 1999;10(Suppl. 3): Abstract 452.
   PubMedGoogle Scholar
• Koenigsmann M, Knauf W, Herold M, et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004;45:1821–1827.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378–4384.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010;116:106–114.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204–210.
   PubMed Web of Science ®Google Scholar
• Ozegowski WKD. IMET 3393, a new cytostatic agent of the group of benzimidazole nitrogen mustards. Zbl Pharm 1971;110:1013–1019.
   Google Scholar
• Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309–317.
   PubMed Web of Science ®Google Scholar
• Castegnaro S, Visco C, Chieregato K, et al. Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. Leuk Lymphoma 2012;53:2262–2268.
   PubMed Web of Science ®Google Scholar
• Chow KU, Boehrer S, Geduldig K, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001;86:485–493.
   PubMed Web of Science ®Google Scholar
• Visco C, Castegnaro S, Chieregato K, et al. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cell Mol Dis 2012;48:68–75.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Chow KU, Hoelzer D, et al. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol 2002;29(4 Suppl. 13):12–14.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383–3389.
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas - final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2010;116(Suppl. 1): Abstract 856.
   Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Van der Jagt RH, Kahl BS, et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): the BRIGHT study. Blood 2012;120(Suppl. 1): Abstract 902.
   Google Scholar
• Rummel MJ, Lerchenmuller C, Greil R, et al. Bendamustin-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenstrom's macroglobulinemia: results from a prospective, randomized, multicenter study (StiL NHL 7-2008 - MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214). Blood 2012;120(Suppl. 1): Abstract 2739.
   Web of Science ®Google Scholar
• Salar A, Domingo-Domenech E, Panizo C, et al. Final results of a multicenter phase II trial with bendamustine and rituximab as first line treatment for patients with MALT lymphoma (MALT-2008-01). Blood 2012;120(Suppl. 1): Abstract 3691.
   Web of Science ®Google Scholar
• Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011;29:3389–3395.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807–2812.
   PubMed Web of Science ®Google Scholar
• Fowler NH, Kahanic SP, Forero A, et al. Results of a phase II study with bendamustine and ofatumumab in untreated indolent B-cell non-Hodgkin's lymphoma. Blood 2011;118(Suppl. 1): Abstract 778.
   Web of Science ®Google Scholar
• Hosein PJ, Warsch S, Alizadeh A, et al. Efficacy and safety of bendamustine (BDM) in patients (pts) with mantle cell lymphoma (MCL). J Clin Oncol 2011;29(15 Suppl.): Abstract e18562.
   Google Scholar
• Warsch S, Hosein PJ, Maeda LS, et al. A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leuk Lymphoma 2012;53:1299–1305.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Lamonica D, Gaylor SK, et al. Open-label bendamustine combined with rituximab for treatment of relapsed/refractory mantle-cell lymphoma: efficacy and safety findings. Blood 2012;120(Suppl. 1): Abstract 3662.
   Google Scholar
• Visco C, Finotto S, Zambello R. et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.J Clin Oncol 2013;31:1442–1449.
   PubMed Web of Science ®Google Scholar
• Magni M, Di Nicola M, Carlo-Stella C, et al. Safety, tolerability and activity of ofatumumab, bendamustine and dexamethasone combination as first-line treatment of mantle-cell lymphoma in the elderly: a multicenter study. Blood 2011;118(Suppl. 1): Abstract 1647.
   Web of Science ®Google Scholar
• Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1285–1289.
   PubMed Web of Science ®Google Scholar
• Vacirca J. Bendamustine combined with rituximab for relapsed or refractory diffuse large B-cell lymphoma. Blood 2009;114(Suppl. 1): Abstract 4750.
   Google Scholar
• Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2013;31:2103–2109.
   PubMed Web of Science ®Google Scholar
• Horn J, Kleber M, Hieke S, et al. Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. Ann Hematol 2012;91:1579–1586.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Puccini B, Cortelazzo S, et al. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients: a multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol 2012;91:1013–1022.
   PubMed Web of Science ®Google Scholar
• Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 2011;22:1839–1844.
   PubMed Web of Science ®Google Scholar
• Walter E, Schmitt T, Dietrich S, et al. Rituximab and bendamustine in patients with CD20 + diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma 2012;53:2290–2292.
   PubMed Web of Science ®Google Scholar
• Herold M, Anger G, Hoche D, et al.[Preliminary results of cyclically alternating chemotherapy (CVPP/DBVCy) in advanced Hodgkin's disease]. Med Klin (Munich) 1987;82:345–349.
   PubMed Web of Science ®Google Scholar
• Hoche D, Wutke K, Anger G, et al. [Comparative study of the efficacy of the DBVCy protocol (daunoblastin, bleomycin, vincristine, cytostasan) and the ABVD protocol in advanced Hodgkin's lymphoma. A prospective inter-clinic study within the framework of the Hauptforschungsrichtung Geschwulsterkrankungen]. Arch Geschwulstforsch 1984;54:333–342.
   PubMedGoogle Scholar
• Herold M, Keinert K, Anger G. Risk adapted combined radio- and chemotherapy in Hodgkin's disease - 10-year follow-up. Onkologie 1999;22:310–313.
   Web of Science ®Google Scholar
• D’Elia GM, De Angelis F, Breccia M, et al. Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma. Leuk Res 2010;34:e300–e301.
   PubMed Web of Science ®Google Scholar
• Mian M, Farsad M, Pescosta N, et al. Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation. Ann Hematol 2013;92:121–123.
   PubMed Web of Science ®Google Scholar
• Magyari F, Simon Z, Barna S, et al. Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation. Hematol Oncol 2010;30:98–100.
   Web of Science ®Google Scholar
• Moskowitz AJ, Hamlin PA, Perales M-A, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456–460.
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Angrilli F, D’Arco A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol 2013;160:207–215.
   PubMed Web of Science ®Google Scholar
• Anastasia A, Carlo-Stella C, Corradini P, et al. Bendamustine for relapsed/refractory classical Hodgkin lymphoma after high dose chemotherapy and or allogeneic transplant: a study of Fondazione Italiana Linfomi (FIL). Blood 2012;120(Suppl. 1): Abstract 3652.
   Web of Science ®Google Scholar
• Ghesquieres H, Stamatoullas A, Casasnovas O, et al. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leuk Lymphoma 2013;54:2399–2404.
   PubMed Web of Science ®Google Scholar
• Yong HX, Linn YC, Ong KH, et al. Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia. Leuk Res 2012;36: e163–e165.
   PubMed Web of Science ®Google Scholar
• Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013;31: 104–110.
   PubMed Web of Science ®Google Scholar
• Zaja F, Baldini L, Ferreri AJ, et al. Bendamustine salvage therapy for T cell neoplasms. Ann Hematol 2013;92:1249–1254.
   PubMed Web of Science ®Google Scholar
• Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011;118:3419–3425.
   PubMed Web of Science ®Google Scholar
• Malipatil B, Ganesan P, Sundersingh S, et al. Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. Hematol Oncol Stem Cell Ther 2011;4:157–160.
   PubMedGoogle Scholar
• Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010;66:1039–1049.
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Rosing H, Darwish M, et al. Pharmacokinetics and excretion of (14)C-bendamustine in patients with relapsed or refractory malignancy. Drugs R D 2013;13:17–28.
   PubMedGoogle Scholar
• Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007;59:759–770.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492–1501.
   PubMed Web of Science ®Google Scholar
• Pönisch W, Wiesler J, Wagner I, et al. Impact of bendamustine pretreatment on stem cell mobilization and autologous stem cell transplantation in patients with multiple myeloma. Blood 2011; 118(Suppl. 1): Abstract 1933.
   Web of Science ®Google Scholar